Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
详细信息 查看全文
- 作者：Pashtoon M. Kasi ; kasi.pashtoon@mayo.edu" class="auth_mail" title="E-mail the corresponding author ; Mark R. Litzow ; Mrinal M. Patnaik ; Shahrukh K. Hashmi ; Naseema Gangat
- 关键词：Acute Leukemia ; FMS-like tyrosine kinase-3 (FLT3) inhibitors ; ASP2215 ; Clonal evolution ; Philadelphia chromosome (BCR-ABL) ; Ponatinib
- 刊名：Leukemia Research Reports
- 出版年：2016
- 出版时间：2016
- 年：2016
- 卷：5
- 期：Complete
- 页码：7-10
- 全文大小：642 K
文摘
- •
The article reports on a case of AML that underwent clonal evolution.
- •
We report on novel acquisition of the Philadelphia t(9;22) translocation in AML.
- •
Next generation sequencing maybe helpful in these refractory/relapse cases.
- •
Novel FLT3-inhibitor targeted therapies are another option in patients with AML.
- •
Personalizing cancer treatment based on evolving targets is a viable option.